Viscosupplementation Market is Anticipated to Grow US$ 17.6 Bn By 2030

The global Viscosupplementation market is expected to grow at a CAGR of around 12.37% over the forecast period 2021 to 2030 and expected to reach the market value of around US$ 17.6 billion by 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38461

Growth Factors

Initiatives to increase awareness regarding available treatment, the rising geriatric population, and product advancements are expected to boost market growth during the forecast period. With the growing geriatric population, the burden of osteoarthritis is expected to increase dramatically. As per the Arthritis Foundation, in the U.S., around 54.4 million adults are reported to be diagnosed with doctor-diagnosed arthritis.

Favorable reimbursement policies with respect to the geriatric population are expected to act as an opportunity for market growth. The viscosupplementation business was affected due to the COVID-19 pandemic as many healthcare providers postponed the nonessential patient visits, such as osteoarthritis treatments. 

Report Highlights

Based on product, the market is segmented into single injection, three injections, and five injections. Single-injection emerged as the leading product segment in 2020 with a revenue share of over 45%. The three and five-injection hyaluronic acid viscosupplements have been in the market for quite a long time, whereas the single-injection products are relatively newer.

Based on end-use, the market is classified into hospitals and orthopedic clinics (ASCs). The orthopedic clinics/ASCs segment held the largest market share of over 61% in 2020 and is also expected to witness the fastest CAGR during the forecast period due to the high demand for outpatient surgeries. ASCs are outpatient surgery centers that focus on offering same-day surgical care, including preventive (surgical) and diagnostic procedures.

ASCs can perform same-day surgeries for ACL surgery, hip, knee, & shoulder replacements, and others. These surgeries are less complicated and require little to no hospitalization. Furthermore, orthopedic clinics are dedicated to the care of the musculoskeletal system.

Asia Pacific accounted for the largest revenue share of more than 45% in 2020 due to the presence of a large geriatric population, which is more susceptible to disorders, such as osteoarthritis. However, Europe is expected to witness the fastest CAGR during the forecast period due to factors, such as the growing geriatric population and increased investments by market players.

Osteoporosis affects more than 2.5 million women in the U.K. and France every year. With the ruling by Haute Autorité de Santé (HAS), 70% of the cost of scan will be covered by the Caisse Primaire d’Assurance Maladie (CPAM).

Key Players

• Sanofi
• Anika Therapeutics, Inc.
• Seikagaku Corp.
• Zimmer Biomet
• Smith & Nephew PLC
• Ferring Pharmaceuticals B.V.
• Lifecore Biomedical
• LG Life Sciences Ltd.
• Fidia Farmaceutici S.p.A
• F.Hoffmann-La Roche Ltd.

Report Coverage	Details
Market Size	US$ 17.6 billion by 2030
Growth Rate	CAGR of 12.37% From 2021 to 2030
Base Year	2020
Historic Data	2017 to 2020
Forecast Period	2021 to 2030
Segments Covered	Product, end-use
Regional Scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned	Sanofi; Anika Therapeutics, Inc.; Seikagaku Corporation; Zimmer Biomet; Smith & Nephew PLC; Ferring Pharmaceuticals B.V.; Lifecore Biomedical; LG Life Sciences Ltd.; Fidia Farmaceutici S.p.A; F.Hoffmann-La Roche Ltd.

Market Segmentation

• Product
  • Single Injection
  • Three Injection
  • Five Injection
• End-use
  • Hospitals
  • Orthopedic Clinics/Ambulatory Surgical Centers (ASCs)
• Regional
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
  • Middle East & Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38461

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Viscosupplementation Market, By Product

7.1.  Viscosupplementation Market, by Product, 2021-2030

7.1.1.    Single Injection

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Three Injection

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Five Injection

7.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Viscosupplementation Market, By End-use

8.1.  Viscosupplementation Market, by End-use, 2021-2030

8.1.1.    Hospitals

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Orthopedic Clinics/Ambulatory Surgical Centers (ASCs)

8.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Viscosupplementation Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Product (2017-2030)

9.1.2.    Market Revenue and Forecast, by End-use (2017-2030)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.1.3.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.1.4.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Product (2017-2030)

9.2.2.    Market Revenue and Forecast, by End-use (2017-2030)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.3.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.4.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.5.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.2.6.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Product (2017-2030)

9.3.2.    Market Revenue and Forecast, by End-use (2017-2030)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.3.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.4.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.5.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.3.6.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Product (2017-2030)

9.4.2.    Market Revenue and Forecast, by End-use (2017-2030)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.3.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.4.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.5.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, by Product (2017-2030)

9.4.6.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Product (2017-2030)

9.5.2.    Market Revenue and Forecast, by End-use (2017-2030)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, by Product (2017-2030)

9.5.3.2.        Market Revenue and Forecast, by End-use (2017-2030)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, by Product (2017-2030)

9.5.4.2.        Market Revenue and Forecast, by End-use (2017-2030)

Chapter 10.  Company Profiles

10.1.              Sanofi

10.1.1.  Company Overview

10.1.2.  Product Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              Anika Therapeutics, Inc.

10.2.1.  Company Overview

10.2.2.  Product Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              Seikagaku Corp.

10.3.1.  Company Overview

10.3.2.  Product Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              Zimmer Biomet

10.4.1.  Company Overview

10.4.2.  Product Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Smith & Nephew PLC

10.5.1.  Company Overview

10.5.2.  Product Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Ferring Pharmaceuticals B.V.

10.6.1.  Company Overview

10.6.2.  Product Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              Lifecore Biomedical

10.7.1.  Company Overview

10.7.2.  Product Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              LG Life Sciences Ltd.

10.8.1.  Company Overview

10.8.2.  Product Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.              Fidia Farmaceutici S.p.A

10.9.1.  Company Overview

10.9.2.  Product Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.           F.Hoffmann-La Roche Ltd.

10.10.1.               Company Overview

10.10.2.               Product Offerings

10.10.3.               Financial Performance

10.10.4.               Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38461

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com